Aerovate Therapeutics’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Aerovate Therapeutics is a biotechnology company that develops and commercializes novel therapeutics for the treatment of cardiopulmonary diseases. Read more

Benjamin T Dake's photo - President of Aerovate Therapeutics

President

Benjamin T Dake

CEO Approval Rating

90/100

Founded:

2019

Status:

Est. Annual Revenue
Est. Employees

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Cardurion is perceived as one of Aerovate Therapeutics's biggest rivals. Cardurion was founded in 2017, and is headquartered in Boston, Massachusetts. Like Aerovate Therapeutics, Cardurion also competes in the Biotechnology space. Cardurion generates $4M more revenue vs. Aerovate Therapeutics.

InCarda is a top competitor of Aerovate Therapeutics. InCarda is a Private company that was founded in 2009 in Newark, California. InCarda is in the Pharmaceuticals industry. Compared to Aerovate Therapeutics, InCarda has 6 more employees.

Verve Therapeutics is Aerovate Therapeutics's #3 rival. Verve Therapeutics is headquartered in Cambridge, Massachusetts, and was founded in 2018. Like Aerovate Therapeutics, Verve Therapeutics also works within the Biotechnology sector. Verve Therapeutics generates ∞% the revenue of Aerovate Therapeutics.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is $ < 1M a good estimate for Aerovate Therapeutics's revenue?

Acquisitions

No recent acquisitions found related to Aerovate Therapeutics

Aerovate Therapeutics Funding History

$2.5M$75.1M

Since Aerovate Therapeutics was founded in 2019, it has participated in 2 rounds of funding. In total Aerovate Therapeutics has raised $75.1M. Aerovate Therapeutics' last funding round was on Aug 2020 for a total of $72.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Aug 2020
$72.6M

RA Capital Management

Debt
Dec 2019
$2.5M

Total Funding: $75.1M

Since Aerovate Therapeutics was founded in 2019, it has participated in 2 rounds of funding. In total Aerovate Therapeutics has raised $75.1M. Aerovate Therapeutics' last funding round was on Aug 2020 for a total of $72.6M

Investments

No recent investments found related to Aerovate Therapeutics

Aerovate Therapeutics News

August 6, 2020Boston Citybizlist

Aerovate Therapeutics Emerges From RA Capital Incubator With $72.6 Million Funding

Aerovate Therapeutics, Inc., has closed on $72.6 million in Series A funding to advance trials of AV-... See more »
August 6, 2020Endpoints News

RA Capital-backed Aerovate launches with $72.6M to treat PAH with a repurposed cancer med

The landmark cancer drug imatinib has been on the market since 2001, first sold by Novartis as Gleeve... See more »

Headquarters

200 Berkeley Street 18th Floor

Boston, Massachusetts02116

617-778-2494

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Aerovate Therapeutics is a biotechnology company that develops and commercializes novel therapeutics for the treatment of cardiopulmonary diseases. Aerovate Therapeutics was founded in 2019. Aerovate Therapeutics' headquarters is located in Boston, Ma...

CEO

Aerovate Therapeutics's President, Benjamin T Dake, currently has an approval rating of 90%. Aerovate Therapeutics's primary competitors are Cardurion, InCarda & Verve Therapeutics.

Website

aerovatetx.com

Frequently Asked Questions about Aerovate Therapeutics

  1. When was Aerovate Therapeutics founded?

    Aerovate Therapeutics was founded in 2019
  2. Who is Aerovate Therapeutics's CEO?

    Aerovate Therapeutics's CEO is Benjamin T Dake
  3. How much revenue does Aerovate Therapeutics generate?

    Aerovate Therapeutics generates $ < 1M in revenue
  4. How much funding does Aerovate Therapeutics have?

    Aerovate Therapeutics has historically raised $75.1M in funding
  1. Where is Aerovate Therapeutics's headquarters?

    Aerovate Therapeutics's headquarters is in Boston Massachusetts, USA
  2. How many employees does Aerovate Therapeutics have?

    Aerovate Therapeutics has 15 employees
  3. What sector does Aerovate Therapeutics operate in?

    Aerovate Therapeutics is in Biotechnology
  4. Who are Aerovate Therapeutics's competitors?

    Aerovate Therapeutics's top competitors are Cardurion, InCarda, Verve Therapeutics